1. ICH E14/S7B Implementation Working Group.Clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential questions and answers draft version August 2020.https://database.ich.org/sites/default/files/ICH_E14‐S7B_QAs_Step2_2020_0827_0.pdf. Accessed April 30 2021.
2. ICH Harmonized Tripartite Guideline S7B.Safety pharmacology assessment of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals.https://www.ich.org/page/safety-guidelines. Accessed April 30 2021.
3. ICH E14 the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non‐antiarrhythmic drugs.https://www.ich.org/page/efficacy-guidelines. Accessed April 30 2021.
4. ICH webinar: new approaches for an integrated nonclinical‐clinical QT/proarrhythmic risk assessment.https://www.fda.gov/drugs/news-events-human-drugs/new-approaches-integrated-nonclinical-clinical-qtproarrhythmic-risk-assessment-10152020-10162020. Published October 2020. Accessed April 30 2021.
5. Torsade de pointes